Парикальцитол – новые возможности оптимизации нефропротективной стратегии и лечения вторичного гиперпаратиреоза


А.А. Плотникова, Л.Ю. Милованова, Ю.С. Милованов

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздравсоцразвития России, Москва
Обсуждаются возможности коррекции нарушений фосфорно-кальциевого обмена с помощью паракальцитола при хронической болезни почек с целью улучшения сердечно-сосудистого прогноза и торможения прогрессирования почечной недостаточности.

Литература



  1. Agarwal R, Acharya M, Tian J., et al.: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68(6): 2823—2828.

  2. Coyne D, Acharya M., Qiu P. et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 2006; 47: 263-276.

  3. Милованова Л.Ю., Милованов Ю.С., Козловская Л.В. Нарушения фосфорно-кальциевого обмена при хронической болезни почек III-V стадий. Клин. нефрол. 2011; 1: 58-68

  4. Milovanova L., Milovanov Y., Plotnikova A. Phosphorus and calcium Metabolism Disorders Associated with Chronic Kidney Disease Stade III-IV (Systematic rewiew and meta-analysis). Chronic Kidney Disease and Renal Transplantation. Ed. By M. Sahay. 2011; 94-118.

  5. Милованов Ю.С., Козловская Л.В., Милованова Л.Ю. Место метаболита витамина D2 парикальцитола в нефропротективной стратегии при хронической болезни почек. Тер. архив. 2011; 6: 70-73.

  6. Milovanov Y.S., Milovanova L.Y., Kozlovskaya L.V. Role of Vitamin D Receptor Selective Activator Paricalcitol in Nephroprotective Strategy in Chronic Kidney Disease. Int J Biomed 2011; 1(4): 199-203.

  7. Goodman W.G., Goldin J., Kuizon B.D. et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000; 342: 1478-1483.

  8. Block G.A., Klassen P.S., Lazarus J.M. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004; 15: 2208-2218.

  9. Stevens L.A., Djurdjev O., Cardew S. et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J. Am. Soc. Nephrol. 2004; 15: 770-779.

  10. Hansen D., Rasmussen K., Pedersen S.M. et al. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol. Dial. Transplant. 2012; 27(6): 2263-2269.

  11. Krajisnik T., Bjorklund P., Marsel R. et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1-alfa-hydroxylaseexpression in cultured bovine parathyroid cells. J. Endocrinol. 2007; 195: 125-131.

  12. Foley R.N., Murray A.M., Li S. et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am. Soc. Nephrol. 2005; 16(2): 489-495.

  13. Blacher J., Guerin A.P., Pannier B. et al. Arterial calcification, arterial stiffness, and cardiovascular risk I end-stage renal disease. Hypertension. 2001; 38: 938-942.

  14. Wang AY-M., Wang M., Woo J. et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am. Soc. Nephrol. 2003;14(1):159-168.

  15. Okuno S., Ishimura E., Kitatani K., et al. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients.American Journal of Kidney Diseases. 2007; 49(3): 417-425.

  16. Sigrist M.K., Taal M.W., Bungay P. et al. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin. J Am. Soc. Nephrol. 2007; 2(6): 1241-1248.

  17. Ogawa T., Ishida H., Akamatsu M. et al. Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients. Int. Urol. Nephrol. 2010; 42(1): 187-194.

  18. Abdelmalek J.A., Stark P., Walther C.P. et al. Associations between coronary calcification on chest radiographs and mortality in hemodialysis patients. Am. J Kidney Dis. 2012; 7:124-134.

  19. Adragao T., Pires A., Branco P. et al. Ankle--brachial index, vascular calcifications and mortality in dialysis patients. Nephrol. Dial. Transplant. 2012;27(1): 318-325.

  20. Noordzij M., Cranenburg E.M., Engelsman L.F. et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol. Dial. Transplant. 2011;26(5):1662-1669.

  21. Sprague S.M., Llach F., Amdahl M. et al. Paricacitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483-1490.

  22. Lindberg J., Martin K.J., Gonzales E.A. et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin. Nephrol. 2001; 56: 315-323.

  23. Teng M., Wolf M., Lowrie E. et al. Survival of Patients Undergoing hemodialysis with paricalcitol or Calcitriol therapy. New. Engl. J. Med. 2003;349:446-456.

  24. Kalantar-Zadeh K., Kuwae N., Regidor D.L. et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.

  25. Kovesdy C.P., Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008;73:1355-1363.

  26. Kalantar-Zadeh K., Kovesdy C.P. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin. J. Am .Soc. Nephrol. 2009; 4: 1529-1539.

  27. Tonbul H.Z., Solak Y., Atalay H. Efficacy and tolerability of intravenousparicalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Ren. Fail. 2012;34(3):297-303

  28. Block G.A., Zeig S., Sugihara J. et al. Combined therapy with cinacalcet and low doses ofvitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2008;23:2311-2318.

  29. Fishbane S., Shapiro W.B., Corry D.B. et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin. J. Am. Soc. Nephrol. 2008; 3:1718-1725.

  30. Ketteler M., Martin K.J., Cozzolino M. et al. Paricalcitol-versus cinacalcet- centered therapy for secondary hyperparathyroidism in patients receiving hemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol. Dial. Transplant. 2012;10:1093-1105.


Об авторах / Для корреспонденции


Плотникова А.А. – ГБОУ ВПО Первый МГМУ им. И.М. Сеченова им. И.М. Сеченова Минздравсоцразвития России
Милованова С.Ю. – старший научный сотрудник лаборатории ревматологических проблем заболеваний печени ФГБУ НИИ Ревматологии РАМН, к.м.н.;
Милованов Ю.С. – доцент кафедры нефрологии и гемодиализа ФППОВ, ведущий научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГБОУ ВПО Первый МГМУ им. И.М. Сеченова им. И.М. Сеченова Минздравсоцразвития России, д.м.н.


Похожие статьи


Бионика Медиа